Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. has been granted orphan drug designation by the U.S. Food and Drug Administration for its treatment of keratoconus, a degenerative eye disease found to be the leading cause of corneal transplants in the U.S.

Click logo to view full story.